| Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus (NCT00133367) | Massachusetts General Hospital | 2005-08-01 |
| A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma (NCT00361088) | H. Lee Moffitt Cancer Center and Research Institute | 2005-08-01 |
| UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma (NCT00569868) | University of Arkansas | 2005-08-01 |
| S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT00124579) | SWOG Cancer Research Network | 2005-08-01 |
| Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases (NCT00309842) | Masonic Cancer Center, University of Minnesota | 2005-07-28 |
| Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy (NCT00571168) | Heidelberg University | 2005-07-01 |
| A Phase II Study of Umbilical Cord Blood Transplantation (NCT00676806) | Tufts Medical Center | 2005-07-01 |
| Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma (NCT00148317) | Weill Medical College of Cornell University | 2005-06-01 |
| Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants (NCT00307086) | H. Lee Moffitt Cancer Center and Research Institute | 2005-06-01 |
| Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma (NCT00116961) | University of Michigan Rogel Cancer Center | 2005-06-01 |
| Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma (NCT00216151) | Hoosier Cancer Research Network | 2005-06-01 |
| IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma (NCT00200681) | Nantes University Hospital | 2005-06-01 |
| Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients (NCT00382694) | Nordic Myeloma Study Group | 2005-05-01 |
| A Phase I Trial of ZIO-101 in Hematologic Cancers (NCT00592046) | Alaunos Therapeutics | 2005-05-01 |
| Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study (NCT00793650) | Emory University | 2005-05-01 |
| A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease (NCT00412321) | Centocor, Inc. | 2005-05-01 |
| BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma (NCT00346255) | ImmunoGen, Inc. | 2005-04-01 |
| AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone (NCT00395967) | Genzyme, a Sanofi Company | 2005-04-01 |
| Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma (NCT00458653) | Beth Israel Deaconess Medical Center | 2005-04-01 |
| S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma (NCT00109889) | SWOG Cancer Research Network | 2005-04-01 |
| Simvastatin as Inhibitor of Cell Adhesion Mediated Drug Resistance in Patients With Refractory Multiple Myeloma. (NCT00399867) | Ludwig-Maximilians - University of Munich | 2005-04-01 |
| An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy (NCT00216697) | Janssen Pharmaceutical K.K. | 2005-03-01 |
| Comparison Between FDG-PET and MRI for the Assessment of Response to Intensive Chemotherapy in Multiple Myeloma Patients. (NCT00200668) | Nantes University Hospital | 2005-03-01 |
| A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma (NCT00241371) | Washington University School of Medicine | 2005-03-01 |
| ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells (NCT00400556) | Peter MacCallum Cancer Centre, Australia | 2005-03-01 |
| Unrelated Donor Stem Cell Transplantation (NCT01364363) | Scripps Health | 2005-03-01 |
| A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma (NCT00229203) | PharmaMar | 2005-02-01 |
| UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients (NCT00111748) | University of Arkansas | 2005-02-01 |
| Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3 (NCT00866138) | AB Science | 2005-02-01 |
| A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma (NCT00097981) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2005-01-01 |
| Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients (NCT00103662) | Genzyme, a Sanofi Company | 2005-01-01 |
| AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF (NCT00396266) | Genzyme, a Sanofi Company | 2005-01-01 |
| Behavioral Intervention For BMT/SCT Survivors (NCT00579917) | Memorial Sloan Kettering Cancer Center | 2005-01-01 |
| Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma (NCT00131261) | Valerio Therapeutics | 2005-01-01 |
| Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma (NCT00103506) | Janssen Research & Development, LLC | 2004-12-01 |
| Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma (NCT00151203) | Weill Medical College of Cornell University | 2004-12-01 |
| Stage I Multiple Myeloma Treatment (NCT00733538) | Centre Hospitalier Universitaire de Nice | 2004-12-01 |
| VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma (NCT00111319) | Millennium Pharmaceuticals, Inc. | 2004-12-01 |
| Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma (NCT00427765) | M.D. Anderson Cancer Center | 2004-12-01 |
| Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma (NCT00099047) | National Cancer Institute (NCI) | 2004-11-01 |
| S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma (NCT00064038) | SWOG Cancer Research Network | 2004-11-01 |
| Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma (NCT00095680) | Scios, Inc. | 2004-11-01 |
| Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma (NCT00113841) | M.D. Anderson Cancer Center | 2004-11-01 |
| VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands (NCT00440765) | Janssen-Cilag B.V. | 2004-11-01 |
| Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients (NCT00358020) | University of Turin, Italy | 2004-11-01 |
| Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma (NCT00985907) | University of California, San Francisco | 2004-10-28 |
| A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma (NCT00516191) | University of California, San Francisco | 2004-10-01 |
| A Multiple Myeloma Trial in Patients With Bone Metastases (NCT00104104) | Novartis Pharmaceuticals | 2004-10-01 |
| Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients (NCT00322842) | Genzyme, a Sanofi Company | 2004-09-01 |
| Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma (NCT00287872) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2004-09-01 |
| Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies (NCT00513318) | University of California, San Francisco | 2004-08-01 |
| Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma (NCT00153933) | Dana-Farber Cancer Institute | 2004-08-01 |
| The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma (NCT00459069) | Beth Israel Deaconess Medical Center | 2004-07-01 |
| Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma (NCT00135187) | University of Michigan Rogel Cancer Center | 2004-07-01 |
| Bortezomib With Melphalan and Prednisone for Multiple Myeloma (NCT00734149) | Duke University | 2004-07-01 |
| Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma (NCT00201695) | Ohio State University Comprehensive Cancer Center | 2004-07-01 |
| Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization. (NCT00299780) | Massachusetts General Hospital | 2004-07-01 |
| Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma (NCT00087867) | Scios, Inc. | 2004-06-01 |
| Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation (NCT00185757) | Stanford University | 2004-06-01 |
| UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients (NCT00113919) | University of Arkansas | 2004-06-01 |
| Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma (NCT00090493) | University of Arkansas | 2004-06-01 |
| A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients (NCT00752518) | Janssen Pharmaceutical K.K. | 2004-05-01 |
| Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies (NCT00241358) | Washington University School of Medicine | 2004-05-01 |
| Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma (NCT00193557) | SCRI Development Innovations, LLC | 2004-05-01 |
| Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma (NCT00086216) | Callisto Pharmaceuticals | 2004-05-01 |
| Autologous Transplant for Multiple Myeloma (NCT00177047) | Masonic Cancer Center, University of Minnesota | 2004-04-20 |
| Family Study of Lymphoproliferative Disorders (NCT00626496) | Mayo Clinic | 2004-04-01 |
| Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. (NCT00242528) | Novartis | 2004-04-01 |
| Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients (NCT00322387) | Genzyme, a Sanofi Company | 2004-04-01 |
| Study Comparing STR (Skeletal Targeted Radiotherapy) Plus Melphalan to Melphalan Alone, With Stem Cell Transplant in Multiple Myeloma (NCT00083564) | Poniard Pharmaceuticals | 2004-03-01 |
| Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor (NCT00304720) | Colorado Blood Cancer Institute | 2004-03-01 |
| Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients (NCT00661544) | M.D. Anderson Cancer Center | 2004-03-01 |
| Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma (NCT00079716) | Seagen Inc. | 2004-03-01 |
| Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients (NCT00322491) | Genzyme, a Sanofi Company | 2004-03-01 |
| Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma (NCT00581919) | University of Wisconsin, Madison | 2004-02-01 |
| Post Transplant Donor Lymphocyte Infusion (NCT00167180) | Masonic Cancer Center, University of Minnesota | 2004-01-01 |
| Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma (NCT00504634) | M.D. Anderson Cancer Center | 2004-01-01 |
| Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II (NCT00093028) | University of Arkansas | 2004-01-01 |
| CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis (NCT00091260) | Vaishali Sanchorawala | 2004-01-01 |
| S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis (NCT00064337) | SWOG Cancer Research Network | 2004-01-01 |
| UARK 2003-33, Total Therapy III (NCT00081939) | University of Arkansas | 2004-01-01 |
| Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma (NCT00440635) | Janssen-Cilag International NV | 2004-01-01 |
| A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004) (NCT00109109) | Merck Sharp & Dohme LLC | 2003-12-01 |
| CP-751,871 Treatment For Patients With Multiple Myeloma (NCT01536145) | Pfizer | 2003-12-01 |
| Protein Tyrosine Kinases (PTK) in Multiple Myeloma (NCT00165347) | Dana-Farber Cancer Institute | 2003-12-01 |
| UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma (NCT00113932) | University of Arkansas | 2003-12-01 |
| Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders. (NCT00145652) | Sundsvall Hospital | 2003-12-01 |
| Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) (NCT00075829) | National Heart, Lung, and Blood Institute (NHLBI) | 2003-12-01 |
| Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma (NCT00153920) | Dana-Farber Cancer Institute | 2003-12-01 |
| Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma (NCT00067639) | M.D. Anderson Cancer Center | 2003-12-01 |
| Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer (NCT00255684) | University of Rochester | 2003-12-01 |
| S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. (NCT00919139) | SWOG Cancer Research Network | 2003-11-01 |
| Xcellerated T CellsTM in Patients With Multiple Myeloma (NCT00078065) | Xcyte Therapies | 2003-11-01 |
| Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma (NCT01296503) | Grupo de Estudos Multicentricos em Onco-Hematologia | 2003-10-01 |
| Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma (NCT00400686) | The Cleveland Clinic | 2003-09-01 |
| Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant (NCT00089453) | University of Arkansas | 2003-09-01 |
| Therapeutic Research in Multiple Myeloma (NCT00572338) | University of Arkansas | 2003-08-01 |
| Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NCT00337506) | Nantes University Hospital | 2003-08-01 |
| Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma (NCT00118339) | Fred Hutchinson Cancer Center | 2003-07-01 |
| Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma (NCT00065351) | Celgene | 2003-07-01 |